• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:34:00 PM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    SC 13G/A 1 cai_13gam3dec312020.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    CAI International, INC.

    (Name of Issuer)

     

    Common Stock, PAR VALUE $0.0001 per share

    (Title of Class of Securities)

     

    12477X106

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

      

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     

      

    CUSIP No.  12477X106
    (1) Names of Reporting Persons
      Park West Asset Management LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Delaware  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 1,364,843*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 1,364,843*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      1,364,843*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      7.7%*  
    (12) Type of Reporting Person
      IA  
                   

    * See Item 4 for additional information.

     

     

     
     

      

    CUSIP No.  12477X106
    (1) Names of Reporting Persons
      Park West Investors Master Fund, Limited  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      Cayman Islands  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 1,241,713*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 1,241,713*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      1,241,713*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      7.0%*  
    (12) Type of Reporting Person
      CO  
                   

    * See Item 4 for additional information.

     

     

     
     

     

    CUSIP No.  12477X106
    (1) Names of Reporting Persons
      Peter S. Park  
    (2) Check the Appropriate Box if a Member of a Group (a) [    ]  
      (b) [    ]  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States of America  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 0    
      (6) Shared Voting Power: 1,364,843*  
      (7) Sole Dispositive Power: 0    
      (8) Shared Dispositive Power: 1,364,843*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      1,364,843*  
    (10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
      [    ]  
    (11) Percent of Class Represented by Amount in Row (9)
      7.7%*  
    (12) Type of Reporting Person
      IN  
                   

    * See Item 4 for additional information.

     

     

     
     

      

    Item 1(a).  Name Of Issuer:
     

     CAI International, Inc., a Delaware corporation (the “Company”)

     

    Item 1(b).  Address of Issuer’s Principal Executive Offices:
     

    Steuart Tower, 1 Market Plaza, Suite 2400

    San Francisco, California 94105

     

    Item 2(a).  Name of Person Filing:
     

    This report on Schedule 13G (this “Schedule 13G”) is being jointly filed by (i) Park West Asset Management LLC (“PWAM”), a Delaware limited liability company, (ii) Park West Investors Master Fund, Limited (“PWIMF”), a Cayman Islands exempted company, and (iii) Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”).

     

    Item 2(b).  Address of Principal Business Office or, if None, Residence:
     

    The address for the Reporting Persons is: 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.

     

    Item 2(c).  Citizenship:
     

    PWAM is organized under the laws of the State of Delaware. PWIMF is a Cayman Islands exempted company. Mr. Park is a citizen of the United States.

     

    Item 2(d).  Title of Class of Securities:
       Common Stock, par value $0.0001 per share (“Common Stock”).
    Item 2(e).  CUSIP No.:
       12477X106
    Item 3. If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
     

    Not Applicable.

     

         

     

     

     
     

     

    Item 4.  Ownership:  
     

    As reported in the cover pages to this report, the ownership information with respect to each of PWAM and Mr. Park is as follows:

     

     
      (a) Amount Beneficially Owned: 1,364,843*  
      (b) Percent of Class: 7.7%*  
      (c) Number of Shares as to which such person has:    
      (i)   Sole power to vote or to direct the vote: 0    
      (ii)   Shared power to vote or to direct the vote: 1,364,843*  
      (iii)  Sole power to dispose or to direct the disposition of: 0    
      (iv)  Shared power to dispose or to direct the disposition of: 1,364,843*  
               

     

     

    As reported in the cover pages to this report, the ownership information with respect to PWIMF is as follows:

     

     
      (a) Amount Beneficially Owned: 1,241,713*  
      (b) Percent of Class: 7.0%*  
      (c) Number of Shares as to which such person has:    
      (i)   Sole power to vote or to direct the vote: 0    
      (ii)   Shared power to vote or to direct the vote: 1,241,713*  
      (iii)   Sole power to dispose or to direct the disposition of: 0    
      (iv)   Shared power to dispose or to direct the disposition of: 1,241,713*  
               

     

      * PWAM is the investment manager to PWIMF and Park West Partners International, Limited, a Cayman Islands exempted company (collectively, the “PW Funds”). Mr. Park, through one or more affiliated entities, is the controlling manager of PWAM. As of December 31, 2020, PWAM and Mr. Park may be deemed to beneficially own 1,364,843 shares of Common Stock held in the aggregate by the PW Funds.

     

    The reported beneficial ownership percentage is based upon approximately 17,742,443 shares of Common Stock issued and outstanding as of October 31, 2020, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2020.

     
     

     

    Item 5.  Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  [    ]
    Item 6.  Ownership of More Than Five Percent on Behalf of Another Person
       Not Applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       Not Applicable.
    Item 8.  Identification and Classification of Members of the Group
       Not Applicable.
    Item 9.  Notice of Dissolution of Group
       Not Applicable.
    Item 10.  Certification
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

      February 16, 2021  
         
      PARK WEST ASSET MANAGEMENT LLC  
         
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

      

         
      PARK WEST INVESTORS MASTER FUND, LIMITED  
         
      By:  Park West Asset Management LLC, its Investment Manager  
         
      By: /s/ Grace Jimenez  
      Name: Grace Jimenez  
      Title: Chief Financial Officer  

     

     

          /s/ Peter S. Park  
          Peter S. Park  
             

     

     

     

     

     

     

     

     

     

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     
     

     

    Exhibit Index

     

     

    Exhibit

    1.       Joint Filing Agreement, dated as of March 23, 2019, by and among Park West Asset Management LLC, Park West Investors Master Fund, Limited and Peter S. Park (incorporated by reference to Exhibit A to the Schedule 13G filed with the Securities and Exchange Commission on March 23, 2019).

     

     

     

     

     

    Get the next $CAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    7/14/2025$34.00Buy
    Citigroup
    7/14/2025$32.00Outperform
    Wolfe Research
    More analyst ratings

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Poste George exercised 125,000 shares at a strike of $2.44 and covered exercise/tax liability with 139,517 shares, decreasing direct ownership by 6% to 220,237 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:56 PM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley covered exercise/tax liability with 63,509 shares, decreasing direct ownership by 12% to 460,377 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:06 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Halbert David D covered exercise/tax liability with 141,956 shares, decreasing direct ownership by 6% to 2,295,133 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Caris Life Sciences with a new price target

    Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00

    7/14/25 8:49:26 AM ET
    $CAI
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Caris Life Sciences with a new price target

    Guggenheim initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00

    7/14/25 8:49:05 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

    IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. MI Cancer Seek is the first and only test to combine whole exome sequencing (WES) and whole transcriptome sequencing (WTS) with FDA-approved CDx indications for solid tumor profiling in

    8/15/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

    IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking S

    8/13/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Reports Second Quarter 2025 Financial Results

    IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.Completed 50,032 clinical therapy selection cases, an increase of 22.0% over corresponding prior year period.Reported gross margin of 62.7%, a 2,514 bps improvement over corresponding prior year period.Reported net loss

    8/12/25 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Brille Brian J bought $630,000 worth of shares (30,000 units at $21.00) and was granted 132,428 shares (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:30:15 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/14/25 4:05:14 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/13/25 4:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    8/12/25 4:59:53 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Declares Quarterly Dividend

    CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co

    8/27/21 5:49:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Enters into Definitive Agreement to be Acquired by Mitsubishi HC Capital Inc.

    Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count

    6/17/21 7:34:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care